公开(公告)号：EP2699258A2

公开(公告)日：2014-02-26

申请号：EP12771864.1

申请日：2012-04-13

申请人： The United States of America As Represented by the Secretary Department of Health and Human Services

发明人： CHIORINI, John, A. ,  YIN, Hongen

IPC分类号： A61K39/235 ,  A61K48/00 ,  A61K38/17 ,  A61K38/16 ,  A61P29/00

CPC分类号： A61K47/48369 ,  A61K38/1774 ,  A61K39/0008 ,  A61K39/39 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/5254 ,  C12N2750/14143

摘要： The invention relates to a gene transfer-based method to protect a subject from Sjogren's syndrome. The method comprises administering to the subject an AAV virion comprising an AAV vector that encodes a soluble CTLA-4 (sCTLA-4) protein. Also provided are sCTLA-4 proteins and nucleic acid molecules that encode such sCTLA-4 proteins. Also provided are AAV vectors and AAV virions that encode a sCTLA-4 protein.

公开(公告)号：EP2525823A1

公开(公告)日：2012-11-28

申请号：EP11735263.3

申请日：2011-01-21

申请人： F.Hoffmann-La Roche AG

发明人： WATTS, Ryan J. ,  YU, Joy ,  DENNIS, Mark ,  FRESKGARD, Per-Ola ,  TAM, Stephen

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61P25/16 ,  A61K38/17 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K47/48369 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/6849 ,  C07K16/28

摘要： The invention provides shuttle agents and methods of using the same to facilitate the translocation of therapeutic or diagnostic molecules into the CNS.

公开(公告)号：EP1682582A4

公开(公告)日：2008-11-12

申请号：EP04800090

申请日：2004-11-13

申请人： HANMI PHARMACEUTICAL CO LTD

发明人： JUNG SUNG YOUB ,  KIM JIN SUN ,  PARK YOUNG JIN ,  CHOI KI-DOO ,  KWON SE CHANG ,  LEE GWAN SUN

IPC分类号： A61K47/42 ,  C07K19/00 ,  A61K47/48 ,  C07K16/00 ,  C07K16/42 ,  C07K16/46 ,  C12N15/70

CPC分类号： A61K47/68 ,  A61K47/48369 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/61 ,  C07K16/46 ,  C07K19/00 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30

摘要： Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

公开(公告)号：EP1910408A2

公开(公告)日：2008-04-16

申请号：EP06783852.4

申请日：2006-07-20

申请人： Applied NanoSystems B.V.

发明人： LEENHOUTS, Cornelis, Johannes ,  VAN ROSMALEN, Maarten, Leonardus ,  BOSMA, Tjibbe

IPC分类号： C07K14/335 ,  A61K39/39 ,  A61K39/385 ,  A61P31/00 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： A61K47/48369 ,  A61K39/385 ,  A61K47/68 ,  A61K2039/541 ,  A61K2039/55555 ,  A61K2039/6056 ,  A61K2039/6068 ,  A61K2039/622 ,  C07K14/335 ,  C07K16/18 ,  C07K2319/70 ,  C07K2319/705

摘要： The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.

公开(公告)号：EP1625209A4

公开(公告)日：2007-01-03

申请号：EP04775946

申请日：2004-05-06

申请人： SYNTONIX PHARMACEUTICALS INC

发明人： PETERS ROBERT T ,  MEZO ADAM R ,  RIVERA DANIEL S ,  BITONTI ALAN J ,  STATTEL JAMES M ,  LOW SUSAN C

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K1/02 ,  C07K1/06 ,  C07K1/10 ,  C07K1/107 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K16/44 ,  C07K16/46 ,  C12N20060101 ,  C12N5/06 ,  C12N9/64 ,  C12P21/00 ,  C12P21/04

CPC分类号： C07K14/755 ,  A61K38/00 ,  A61K47/48215 ,  A61K47/48369 ,  A61K47/48415 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/60 ,  A61K47/642 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/59 ,  C07K14/61 ,  C07K14/70503 ,  C07K14/745 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/647 ,  C12N9/96 ,  C12Y304/21021 ,  C12Y304/21022

摘要： A chimeric protein is synthesized by a) recombinantly expressing a fusion protein comprising at least a portion of an immunoglobulin constant region and a splicing protein capable of forming a C terminus thioester on the portion of an immunoglobulin constant region; b) adding a thiol cofactor to the fusion protein of a); and c) adding at least one biologically active molecule having an N terminal cysteine.

公开(公告)号：EP1654378A4

公开(公告)日：2006-09-13

申请号：EP04751356

申请日：2004-05-06

申请人： SYNTONIX PHARMACEUTICALS INC

发明人： MEZO ADAM R ,  PETERS ROBERT T

IPC分类号： C07K1/02 ,  A61K38/00 ,  A61K39/395 ,  C07H21/04 ,  C07K1/06 ,  C07K1/10 ,  C07K1/107 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K16/00 ,  C07K16/44 ,  C07K16/46 ,  C12N20060101 ,  C12N5/06 ,  C12N9/64 ,  C12P21/00 ,  C12P21/04

CPC分类号： C07K14/755 ,  A61K38/00 ,  A61K47/48215 ,  A61K47/48369 ,  A61K47/48415 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/60 ,  A61K47/642 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/59 ,  C07K14/61 ,  C07K14/70503 ,  C07K14/745 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/647 ,  C12N9/96 ,  C12Y304/21021 ,  C12Y304/21022

摘要： A chimeric protein is synthesized by a) recombinantly expressing a fusion protein comprising at least a portion of an immunoglobulin constant region and a splicing protein capable of forming a C terminus thioester on the portion of an immunoglobulin constant region; b) adding a thiol cofactor to the fusion protein of a); and c) adding at least one biologically active molecule having an N terminal cysteine.

摘要翻译： 通过以下方法合成嵌合蛋白：a）在免疫球蛋白恒定区的部分上重组表达包含至少一部分免疫球蛋白恒定区和能够形成C末端硫酯的剪接蛋白的融合蛋白; b）向a）的融合蛋白中加入硫醇辅因子; 和c）加入至少一种具有N末端半胱氨酸的生物活性分子。